Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates

• Type of Material: Article
• Authors: Kizzmekia S Corbett, National Institute of Allergy and Infectious Diseases, NIH, Bethesda; Martha C Nason, National Institute of Allergy and Infectious Diseases, NIH, Bethesda; Britta Flach, National Institute of Allergy and Infectious Diseases, NIH, Bethesda; Matthew Gagne, National Institute of Allergy and Infectious Diseases, NIH, Bethesda; Sarah O' Connell, National Institute of Allergy and Infectious Diseases, NIH, Bethesda; Timothy S Johnston, National Institute of Allergy and Infectious Diseases, NIH, Bethesda; Shruti N Shah, National Institute of Allergy and Infectious Diseases, NIH, Bethesda; Venkata Viswanadh Edara, Emory University; Katharine Floyd, Emory University; Lilin Lai, Emory University; Charlene McDanal, Duke University; Jospeh R Francica, National Institute of Allergy and Infectious Diseases, NIH, Bethesda; Barbara Flynn, National Institute of Allergy and Infectious Diseases, NIH, Bethesda; Kai Wu, Moderna Inc; Angela Choi, Moderna Inc; Matthew Koch, Moderna Inc; Olubukola M Abiona, National Institute of Allergy and Infectious Diseases, NIH, Bethesda; Anne P Werner, National Institute of Allergy and Infectious Diseases, NIH, Bethesda; Juan Moliva, National Institute of Allergy and Infectious Diseases, NIH, Bethesda; Shayne F Andrew, National Institute of Allergy and Infectious Diseases, NIH, Bethesda; Mitzi M Donaldson, National Institute of Allergy and Infectious Diseases, NIH, Bethesda; Jonathan Fintzi, National Institute of Allergy and Infectious Diseases, NIH, Bethesda; Dillon R Flebbe, National Institute of Allergy and Infectious Diseases, NIH, Bethesda; Evan Lamb, National Institute of Allergy and Infectious Diseases, NIH, Bethesda; Amy T Noe, National Institute of Allergy and Infectious Diseases, NIH, Bethesda; Saule T Nurmukhambetova, National Institute of Allergy and Infectious Diseases, NIH, Bethesda; Samantha J Provost, National Institute of Allergy and Infectious Diseases, NIH, Bethesda; Anthony Cook, BIOQUAL Inc.; Alan Dodson, BIOQUAL Inc.; Andrew Faudree, BIOQUAL Inc.; Jack Greenhouse, BIOQUAL Inc.; Swagata Kar, BIOQUAL Inc.; Laurent Pessaint, BIOQUAL Inc.; Maciel Porto, BIOQUAL Inc.; Katelyn Steingrebe, BIOQUAL Inc.; Daniel Valentin, BIOQUAL Inc.; Serge Zouantcha, BIOQUAL Inc.; Kevin W Bock, National Institute of Allergy and Infectious Diseases, NIH, Bethesda; Mahnaz Minai, National Institute of Allergy and Infectious Diseases, NIH, Bethesda; Bianca M Nagata, National Institute of Allergy and Infectious Diseases, NIH, Bethesda; Renee van de Wetering, National Institute of Allergy and Infectious Diseases, NIH, Bethesda; Seyhan Boyoglu-Barnum, National Institute of Allergy and Infectious Diseases, NIH, Bethesda; Kwanyee Leung, National Institute of Allergy and Infectious Diseases, NIH, Bethesda; Wei Shi, National Institute of Allergy and Infectious Diseases, NIH, Bethesda; Eun Sung Yang, National Institute of Allergy and Infectious Diseases, NIH, Bethesda; Yi Zhang, National Institute of Allergy and Infectious Diseases, NIH, Bethesda; John-Paul M Todd, National Institute of Allergy and Infectious Diseases, NIH, Bethesda; Lingshu Wang, National Institute of Allergy and Infectious Diseases, NIH, Bethesda; Gabriela S Alvarado, National Institute of Allergy and Infectious Diseases, NIH, Bethesda; Hanne Andersen, BIOQUAL Inc.; Kathryn E Foulds, National Institute of Allergy and Infectious Diseases, NIH, Bethesda; Darin K Edwards, Moderna Inc; John R Mascola, National Institute of Allergy and Infectious Diseases, NIH, Bethesda; Ian Moore, Emory University; Mark G Lewis, BIOQUAL Inc.; Andrea Carfi, Moderna Inc; David Monterfiori, Duke University; Mehul Suthar, Emory University; Adrian McDermott, National Institute of Allergy and Infectious Diseases, NIH, Bethesda; Mario Roederer, National Institute of Allergy and Infectious Diseases, NIH, Bethesda; Nancy J Sullivan, National Institute of Allergy and Infectious Diseases, NIH, Bethesda; Daniel C Douek, National Institute of Allergy and Infectious Diseases, NIH, Bethesda; Barney Graham, National Institute of Allergy and Infectious Diseases, NIH, Bethesda; Robert A Seder, National Institute of Allergy and Infectious Diseases, NIH, Bethesda
• Language: English
• Date: 2021-09-17
• Publisher: AMER ASSOC ADVANCEMENT SCIENCE
• Publication Version: Author Accepted Manuscript (After Peer Review)
• Copyright Statement: © 2021 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.
• Final Published Version (URL): http://dx.doi.org/10.1126/science.abj0299
• Title of Journal or Parent Work: SCIENCE
• Volume: 373
• Issue: 6561
• Start Page: 1325
• End Page: +
• Grant/Funding Information: Intramural Research Program of the VRC, NIAID, NIH; Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority, Contract 75A50120C00034; Undergraduate Scholarship Program, Office of Intramural Training and Education, Office of the Director, NIH (K.S.C.); NIAID Research Participation Program, administered by the Oak Ridge Institute for Science and Education through an interagency agreement between the U.S. Department of Energy and NIAID (R.W.); Emory Executive Vice President for Health Affairs Synergy Fund Award (M.S.S.); Pediatric Research Alliance Center for Childhood Infections and Vaccines and Children’s Healthcare of Atlanta (M.S.S.); Woodruff Health Sciences Center 2020 COVID-19 CURE Award (M.S.S.).
• Keywords: LIGHT; DIELECTRIC LASER ACCELERATION; OPTICAL-EXCITATIONS; GENERATION; COVID-19; Science & Technology - Other Topics; Science & Technology; IMMUNIZATION; NEUTRALIZATION; SUB-RELATIVISTIC ELECTRONS; QUANTUM WALKS; Multidisciplinary Sciences; INFECTION

Abstract

Immune correlates of protection can be used as surrogate endpoints for vaccine efficacy. Here, nonhuman primates (NHPs) received either no vaccine or doses ranging from 0.3 to 100 mg of the mRNA-1273 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine. mRNA-1273 vaccination elicited circulating and mucosal antibody responses in a dose-dependent manner. Viral replication was significantly reduced in bronchoalveolar lavages and nasal swabs after SARS-CoV-2 challenge in vaccinated animals and most strongly correlated with levels of anti-S antibody and neutralizing activity. Lower antibody levels were needed for reduction of viral replication in the lower airway than in the upper airway. Passive transfer of mRNA-1273-induced immunoglobulin G to naïve hamsters was sufficient to mediate protection. Thus, mRNA-1273 vaccine-induced humoral immune responses are a mechanistic correlate of protection against SARS-CoV-2 in NHPs.